The comparable effects observed in vivo and in vitro demonstrated that TTD is an NR4A1 antagonist that acts as an antagonist to inhibit NR4A1-dependent pro-oncogenic pathways, and this confirms a potential clinical role for TTD as another NR4A1 antagonist in pancreatic cancer chemotherapy. This evidence concerns the gene NR4A1 and familial pancreatic carcinoma.